The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter 
Professionals >> Visit The Body PROThe Body en Espanol
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

U.S. News

Hope Against Hepatitis C

July 30, 2010

Robust new therapies against hepatitis C virus could begin reaching the market as early as next year, and two protease inhibitors are top candidates. Though infected individuals can remain asymptomatic for decades, about 5 percent to 20 percent of people with HCV will develop cirrhosis over a period of 20 to 30 years, and 1 percent to 5 percent will die of cancer or cirrhosis, according to CDC.


In May, preliminary data from a late-stage clinical trial showed Vertex Pharmaceuticals' experimental drug telaprevir, in combination with existing treatments, had an effective cure rate of 75 percent. Just 44 percent of patients given standard therapy alone, alpha interferon and ribavirin, had a sustained viral response. Many of the patients taking telaprevir needed just a 24-week course, compared with the 24- to 48-week regimen on standard drugs. About half of patients receiving standard treatment either fail to suppress the virus or cannot tolerate the drugs' grueling side effects.

In addition to Vertex's telaprevir, Merck is working on the protease inhibitor boceprevir.

If approved by the Food and Drug Administration (FDA), the new drugs will probably have to be used with interferon for the next five years. However, physicians are hoping that new combination HCV therapies will be developed that would do away with the need for weekly interferon injections. An estimated 300,000 people have failed on the existing therapy. Early data suggest half of these could achieve a sustained response with telaprevir.

Three-quarters of those infected do not know it because they have not been diagnosed. In June, FDA approved a rapid HCV blood test developed by OraSure Technologies. Future oral swab rapid tests might allow health workers to diagnose HCV at churches, street fairs, and other venues.

Back to other news for July 2010

Adapted from:
New York Times
07.22.2010; Andrew Pollack

  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
See Also
Talk to a Physician About HIV/Hepatitis Coinfection in Our "Ask the Experts" Forums

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining: